AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12545149
Drug: Morphine-6-glucuronide (63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-6-glucuronide (63 to 112 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Trial: 12545149
Drug: Morphine (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (26 to 66 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Trial: 10626190
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (2 mg/kg/day) administered during and after the operation for 7 days
Trial: 10626190
Drug: Standard post-operative
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard post-operative intensive therapies (Control)
Trial: 22670856
Drug: Autologous serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous serum (AS) eyedrops diluted at 20%, treatment duration: 2 weeks
Trial: 22670856
Drug: Conventional artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional artificial tears, treatment duration: 2 weeks
Trial: 18818309
Drug: anti‐CTLA‐4 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti‐CTLA‐4 antibody
Trial: 16022747
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (1.5 g daily)
Trial: 10648305
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I - Avoided positive inotropic catecholamines and vasodilators; mechanical ventilation with low tidal volumes < 8 mL/kg, duration of inspiration:expiration = 3:1, peak inspiratory pressures < 18 cm H(2)O
Trial: 10648305
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II - Used positive inotropic catecholamines and vasodilators; mechanical ventilation with high tidal volumes (10‐15 mL/kg) and peak inspiratory pressures up to 50 cm H(2)O
Trial: 1988778
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate 50 mg as an intramuscular depot injection every 3 weeks for 1 year
Trial: 1988778
Drug: Estrogen‐progestogen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen‐progestogen therapy (2 mg 17 beta‐estradiol plus 1 mg norethisterone acetate) daily for 1 year
Trial: 6216814
Drug: Manipulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation therapy (MTG)
Trial: 6216814
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CTG)
Trial: 31560580
Drug: CDK4/6 inhibitor
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitor and an aromatase inhibitor (AI)
Trial: 25491882
Drug: Nasal intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal intermittent positive pressure ventilation (NIPPV) + very early surfactant treatment
Trial: 20561180
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of melatonin daily
Trial: 17660178
Drug: Neomycin 0.35%/polymyxin
RxNorm normalized name: NEOMYCIN 0.35%/POLYMYXIN OPH OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0% (NPH)
Trial: 15683857
Drug: 10% concentrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% concentrated intravenous gammaglobulin
Trial: 15683857
Drug: 5% concentrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% concentrated intravenous gammaglobulin
Trial: 3040815
Drug: Itraconazole 50
RxNorm normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 50 mg before breakfast
Trial: 3040815
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg before breakfast
Trial: 3040815
Drug: Itraconazole 50
RxNorm normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 50 mg with breakfast
Trial: 3040815
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg with breakfast
Trial: 28447203
Drug: 400 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg/day folate
Trial: 28447203
Drug: 800 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 µg/day folate
Trial: 22982085
Drug: Capitalization approach
RxNorm normalized name: acetaminophen / codeine phosphate Oral Suspension [Capital and Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capitalization approach (treatment matched to relative strengths)
Trial: 22982085
Drug: Compensation approach
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compensation approach (treatment matched to relative deficits)
Trial: 15660025
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (4‐12 mg/d)
Trial: 12106837
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy in AMI patients
Trial: 10433575
Drug: Clarithromycin 1000
RxNorm normalized name: clarithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1000 mg b.i.d.
Trial: 1747286
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (30 ng kg‐1 min‐1)
Trial: 1747286
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion during exercise
Trial: 6174041
Drug: Acebutolol, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol, 300 mg three times daily
Trial: 6174041
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release quinidine sulfate in identical doses
Trial: 31651299
Drug: Pre-surgery physiotherapy
RxNorm normalized name: ENSURE PRE-SURGERY LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-surgery physiotherapy for 9 weeks, adherence to ≥12 treatment sessions
Trial: 31651299
Drug: Pre-surgery physiotherapy
RxNorm normalized name: ENSURE PRE-SURGERY LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-surgery physiotherapy for 9 weeks, adherence to 0-11 treatment sessions
Trial: 28803710
Drug: Intrathecal HPβCD
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal HPβCD 900 mg
Trial: 28803710
Drug: Intrathecal HPβCD
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal HPβCD 1200 mg
Trial: 28803710
Drug: Intrathecal HPβCD
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal HPβCD 600 or 900 mg
Trial: 11802520
Drug: Zotepine 150
RxNorm normalized name: zotepine
DrugBank: Zotepine (DB09225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine 150 mg/day
Trial: 11802520
Drug: Haloperidol 9
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 9 mg/day
Trial: 9824170
Drug: Cognitive‐behavioral group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral group treatment (CBT)
Trial: 9824170
Drug: Interactional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactional group treatment (IT)
Trial: 668973
Drug: triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: triamcinolone acetonide (0.25 mg/cm2 of the skin)
Trial: 25851287
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + Vitamin E supplementation (intervention group; n=76)
Trial: 25851287
Drug: Antibiotics (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (control group; n=76)
Trial: 19360499
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy with modified right half-field eye-patching for 4 weeks
Trial: 19360499
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment only for 4 weeks
Trial: 17433315
Drug: Metformin 2.5
RxNorm normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2.5 g/day
Trial: 17433315
Drug: Metformin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1.5 g/day
Trial: 11481350
Drug: Both sequences
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sequences at identical irinotecan doses
Trial: 3185647
Drug: Insulin-dependent diabetics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetics with neuropathy
Trial: 3185647
Drug: Insulin-dependent diabetics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetics without neuropathy
Trial: 30227980
Drug: Aerosolized lidocaine
RxNorm normalized name: Lidocaine Topical Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized lidocaine (10% solution, 70 mg) applied over larynx and trachea
Trial: 30227980
Drug: Cotton swabs
RxNorm normalized name: Cotton Swabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton swabs impregnated with 1 ml of 20 mg lidocaine solution
Trial: 25169589
Drug: Paclitaxel-coated balloon
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-coated balloon (DCB) (3 µg/mm²)
Trial: 23274779
Drug: CMC/PEO gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMC/PEO gel treatment group
Trial: 20953883
Drug: HMB/Glu/Arg (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB/Glu/Arg (24 g dissolved in water twice daily for 8 weeks)
Trial: 14658015
Drug: perindoprilat infusion
RxNorm normalized name: perindoprilat
DrugBank: Perindoprilat (DB14213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindoprilat infusion
Trial: 8096473
Drug: 30-min oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-min oxytocin infusion regimen
Trial: 8096473
Drug: 15-min oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-min oxytocin infusion regimen
Trial: 30396554
Drug: Weekly progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly progesterone vaginal ring (VR)
Trial: 30396554
Drug: Daily progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily progesterone gel
Trial: 27379922
Drug: Tolvaptan (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (7.5 mg) in combination with conventional diuretics (furosemide 20 mg and spironolactone 25 mg)
Trial: 27379922
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (furosemide 20 mg and spironolactone 25 mg)
Trial: 27379922
Drug: Tolvaptan (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (7.5 mg) in combination with conventional diuretics
Trial: 21997865
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (SB) 250 mg twice daily for 5 days
Trial: 20561606
Drug: Transdiagnostic Internet‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic Internet‐based cognitive behavioural treatment (iCBT) program
Trial: 16938157
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg i.v.
Trial: 16938157
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg i.v.
Trial: 11953079
Drug: DNA immunoabsorbent
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA immunoabsorbent therapy
Trial: 81588
Drug: Gamma globulin
RxNorm normalized name: Gamma globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma globulin immunotherapy
Trial: 30196790
Drug: Algorithm including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Algorithm including elevated C-reactive protein ≥30 mg/l
Trial: 22104026
Drug: Local thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local thermal therapy with far‐infrared rays (FIR), 20 minutes per day, twice a week, for 20 sessions
Trial: 22104026
Drug: Local thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local thermal therapy with far‐infrared rays (FIR)
Trial: 3120758
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiotherapy (45 Gy) and chemotherapy (doxorubicin and cyclophosphamide)
Trial: 3120758
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiotherapy and chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil)
Trial: 22236504
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg metyrapone/20 mg oxazepam (low dose)
Trial: 22236504
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg metyrapone/20 mg oxazepam (high dose)
Trial: 19258546
Drug: Calcium (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (2.0 g/d)
Trial: 17630547
Drug: saquinavir/ritonavir 2000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir/ritonavir 2000/100 mg o.d.
Trial: 17630547
Drug: saquinavir/ketoconazole 2000/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir/ketoconazole 2000/400 mg o.d.
Trial: 9238166
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (radiotherapy)
Trial: 9238166
Drug: Cisplatin-containing chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin-containing chemotherapy
Trial: 9238166
Drug: New promising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New promising chemotherapy regimens and new fractionated radiation schedules
Trial: 9238166
Drug: Innovative therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative therapeutic approaches (biotherapies, recombinant cytokines, antitumoral vaccine, gene therapy)
Trial: 22515282
Drug: restrictive oral
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: restrictive oral appliance (restrict‐MMOA)
Trial: 22515282
Drug: free‐MMOA (full‐arch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: free‐MMOA (full‐arch maxillary and mandibular oral appliances with no restrictions of mandibular movements)
Trial: 22515282
Drug: baseline (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baseline (no oral appliance)
Trial: 16643361
Drug: Triazolam administered
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazolam administered orally 75 minutes prior to scheduled atrial shock delivery
Trial: 8972016
Drug: US formulation
RxNorm normalized name: Semaglutide 4 MG Oral Tablet [RYBELSUS FORMULATION R2]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US formulation of Hemofil-M at a dose of 50 u/kg
Trial: 8972016
Drug: Spanish formulation
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish formulation of Hemofil-M at a dose of 50 u/kg
Trial: 6141750
Drug: Alpha-blocker phenoxybenzamine
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker phenoxybenzamine (10-20 mg daily)
Trial: 6141750
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpha-blocker phenoxybenzamine (10-20 mg daily) and beta-blocker sotalol (40-80 mg daily)
Trial: 27022607
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Group: 50 mg/kg MgSO4 intravenously in 150 mL saline
Trial: 27022607
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) Group: 50 mg/kg MgSO4 in 30 mL saline injected intramuscularly
Trial: 27022607
Drug: Control (C)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (C) Group: 30 mL saline injected intramuscularly
Trial: 20576667
Drug: Neurodevelopmental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental treatment
Trial: 12895267
Drug: Interferon A
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon A (10 MU IntronA/day for 2 weeks, followed by 10 MU/2 days for 12 weeks) + ribavirin (1-1.2 g/day)
Trial: 12895267
Drug: Interferon B
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon B (5 MU/day for 14 weeks) + ribavirin (1-1.2 g/day)
Trial: 12895267
Drug: Interferon C
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon C (5 MU/2 days for 14 weeks) + ribavirin (1-1.2 g/day)
Trial: 10907971
Drug: Other dosages
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other dosages of HMG-CoA reductase inhibitors
Trial: 6726981
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of activated charcoal and sorbitol
Trial: 6726981
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of charcoal and cathartic
Trial: 28904371
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose insulin infusion
Trial: 28904371
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose hydrocortisone with high insulin
Trial: 17287298
Drug: Intrabronchial administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrabronchial administration of recombinant surfactant protein C-based surfactant preparation (Venticute)
Trial: 17287298
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment (Venticute)
Trial: 17287298
Drug: Supplementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation of Venticute with synthetic neutral lipid preparation
Trial: 8791050
Drug: Cisplatin 60
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m2 i.v. and epirubicin 60 mg/m2 i.v. every 3 weeks for six cycles, with estramustine phosphate at 10 mg/kg p.o. in two divided daily doses during chemotherapy and until progression.
Trial: 1619006
Drug: Intranasal octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal octreotide 2000 micrograms
Trial: 1619006
Drug: Intranasal octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal octreotide 1000 micrograms
Trial: 1619006
Drug: Intranasal octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal octreotide 500 micrograms
Trial: 1619006
Drug: Subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide 100 micrograms
Trial: 1619006
Drug: Intranasal octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal octreotide (all doses)
Trial: 6095549
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg/die
Trial: 6095549
Drug: Cimetidine 2000
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 2000 mg/die
Trial: 6095549
Drug: Cimetidine 2000
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 2000 mg/die + Pirenzepine 2 X 10 mg/die
Trial: 27139523
Drug: Reduced-intensity treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-intensity treatment with liberalized goals for serum phosphorus and parathyroid hormone (PTH)